X
[{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.5 million","newsHeadline":"GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by GPCR Therapeutics
Filters
Companies By Therapeutic Area
Details:
Bridge Biotherapeutics and GPCR will pursue joint development and commercialization of the CXCR4-LPA1 inhibitor combination therapy and conducting a multinational phase 2a clinical trial of BBT-877, an autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s):
Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Bridge Biotherapeutics
Deal Size: Undisclosed
Upfront Cash: $1.5 million
Deal Type: Licensing Agreement
December 14, 2023
Details:
The company work on unique approach to inhibit two signaling receptors, lysophosphatidic acid receptor 1 (LPA1) and CXCR4, for the effective treatment of Idiopathic Pulmonary Fibrosis (IPF).
Lead Product(s):
Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 10, 2023